Atara Biotherapeutics
ATRA
86 hedge funds and large institutions have $542M invested in Atara Biotherapeutics in 2017 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 24 reducing their positions, and 10 closing their positions.
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
23% more capital invested
Capital invested by funds: $441M → $542M (+$101M)
17% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 24
5% more funds holding
Funds holding: 82 → 86 (+4)
0.42% more ownership
Funds ownership: 3.48% → 3.9% (+0.42%)
74% less call options, than puts
Call options by funds: $750K | Put options by funds: $2.85M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
+$14M |
| 2 |
AG
Artal Group
Luxembourg
|
+$5.91M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$5.48M |
| 4 |
Morgan Stanley
New York
|
+$4.42M |
| 5 |
NC
Nexthera Capital
New York
|
+$4.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$1.52M |
| 2 |
RI
RTW Investments
New York
|
-$1.48M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.47M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$1.09M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$764K |
ATRA Hedge Fund Activity: Q4 2017 in Review
86 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2017, worth a combined $542M — up 23% from $441M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ATRA positions and 10 closed out — a net gain of 4 holders — while 28 added to existing stakes and 24 trimmed.
The largest buyer was Bridger Management, adding an estimated $14M. The largest seller was Neuberger Berman Group, cutting an estimated $1.52M.
- 86 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2017, up from 82 in Q3 2017.
- Funds reported $542M of Atara Biotherapeutics stock for Q4 2017, up 23% quarter-over-quarter.
- 14 funds opened new Atara Biotherapeutics positions in Q4 2017 and 10 closed out, a net change of +4 holders.
- The largest Atara Biotherapeutics buyer in Q4 2017 was Bridger Management, an estimated $14M added.
- The largest Atara Biotherapeutics seller in Q4 2017 was Neuberger Berman Group, an estimated $1.52M sold.
Based on aggregated 13F filings for Q4 2017.